1. Market Research
  2. > Pathology
About 100 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • United States
  • Bristol-Myers Squibb Company

Global Chemotherapy Drugs Market - Opportunities and Forecast (2013-2023)

  • $ 2200
  • March 2019
  • 200 pages

Lymphoma Gastrointestine Others Figure ##: Types of cancer for which clinical trials using chemotherapy drugs treatment are being conducted ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% Source: U. S Clinical Trials Registry GLOBAL THERAPEUTIC CHEMOTHERAPY DRUGS MARKET FIGURE ##: GLOBAL

  • Cancer
  • Chemotherapy
  • Lymphoma
  • Therapy
  • Bristol-Myers Squibb Company

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • United States
  • Bristol-Myers Squibb Company

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 403 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company

Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)

  • $ 1000
  • July 2018
  • 79 pages

Celgene also gains full global rights to JCAR## (lisocabtagene maraleucel; liso-cel), a CD-## targeted CAR-T therapy currently in pivotal trials for relapsed and/ or refractory diffuse large B-cell lymphoma (DLBCL).

  • Lymphoma
  • Therapy
  • World
  • Bristol-Myers Squibb Company
  • Celgene Corporation

Kidney Cancer Therapeutics & Diagnostics Market- Growth, Trends, and Forecasts (2020 – 2025)

  • $ 4250
  • July 2020
  • 135 pages

ADCETRIS is approved for some CD##-expressing lymphomas, while PADCEV is approved for certain metastatic urothelial cancers.

  • Diagnostics
  • Lymphoma
  • Renal Cancer
  • Therapy
  • Bristol-Myers Squibb Company

The State of Personalized/ Precision Medicine

  • $ 7995
  • October 2019
  • 119 pages

BeiGene Ovarian cancer Rhythm Pharmaceuticals Pro-opiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity Denovo Biopharma Diffuse large B-cell lymphoma (DLBCL) Genentech/ Roche Solid tumors GenSight Biologics Leber' s hereditary optic neuropathy (LHON)

  • Lymphoma
  • Therapy
  • United States
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

DNA Next Generation Sequencing Market to 2025 - Global Analysis and Forecasts

  • $ 4550
  • January 2019
  • 246 pages

The global DNA next generation sequencing market is expected to reach US$ 22,716.9 Mn in 2025 from US$ 4,898.5 Mn in 2017. The market is estimated to grow with a CAGR of 21.7% from 2018-2025. The growth ...

  • Biotech Diagnostics
  • DNA
  • Lymphoma
  • Molecular Diagnostics
  • Bristol-Myers Squibb Company

Bladder Cancer Treatment Drugs Markets in China

  • $ 4000
  • May 2020
  • 235 pages

Epirubicin is primarily used against breast and ovarian cancer, gastric cancer, lung cancer, and lymphomas.

  • Bladder Cancer
  • Lymphoma
  • Therapy
  • China
  • Bristol-Myers Squibb Company

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

  • $ 513
  • November 2016
  • 75 pages

Rituxan is the first monoclonal antibody approved for lymphomas.

  • Lymphoma
  • Therapy
  • North America
  • United States
  • Bristol-Myers Squibb Company

Immuno-oncology: Focus on Developments and Opportunities in Immune Checkpoint Modulators

  • $ 7995
  • March 2020
  • 141 pages

In the long term, GlobalData anticipates ICIs having more prominence in the treatment of malignancies such as HL, MM, AML, and other types of lymphomas.

  • Lymphoma
  • Therapy
  • China
  • United States
  • Bristol-Myers Squibb Company

Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU

  • $ 7995
  • September 2018
  • 162 pages

It is indicated for adult patients with R/ R DLBCL and primary mediastinal large B-cell lymphoma (PMBCL).

  • Cancer
  • Lymphoma
  • Oncology
  • Pharmaceutical
  • Bristol-Myers Squibb Company

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

  • $ 4995
  • September 2018
  • 141 pages

However, Humira is packaged with a boxed warning relating to an increased risk of severe infections, such as tuberculosis and bacterial sepsis, and an increased risk of malignancy, such as lymphomas, for patients taking this drug.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Lymphoma
  • Bristol-Myers Squibb Company

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease

  • $ 4995
  • December 2017
  • 160 pages

They also have an increased risk of Parkinson' s disease, and cancers such as myeloma, leukemia and lymphoma.

  • Clinical Trial
  • Genetic Disorder
  • Lymphoma
  • Therapy
  • Bristol-Myers Squibb Company

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • October 2018
  • 124 pages

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027 Summary The Glioblastoma Multiforme (GBM) market is expected to grow from $662.0m in 2017 to $1.4bn in 2027 across the eight majo ...

  • Brain Cancer
  • Lymphoma
  • Therapy
  • United States
  • Bristol-Myers Squibb Company

Biotechnology - Thematic Research

  • $ 1950
  • September 2018
  • 24 pages

The FDA approved two CAR-T cell therapies in 2017: Novartis' Kymriah for acute lymphoblastic leukemia (ALL); and Gilead Sciences' Yescarta for advanced B-cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • United States
  • Amgen Inc.
  • Bristol-Myers Squibb Company

The World Market for Cancer Therapeutics by Product

  • $ 4200
  • November 2015
  • 320 pages

Follicular lymphoma tends to be indolent and diffuse lymphoma tends to be aggressive.

  • Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market

  • $ 4995
  • December 2017
  • 155 pages

Avelumab is being investigated in multiple tumor types, such as breast cancer, ovarian cancer, fallopian tube cancer, melanoma, RCC, HCC, small cell lung cancer, NSCLC, prostate cancer, gastric cancer, CRC, cervical cancer, diffuse large B-cell lymphoma, acute myeloid leukemia, osteosarcoma

  • Cancer
  • Chemotherapy
  • Lymphoma
  • Therapy
  • Bristol-Myers Squibb Company

Global Vasculitis Treatment Market 2017-2021

  • $ 2500
  • June 2017
  • 78 pages

TECHNAVIO.

  • Autoimmune Disease
  • Lymphoma
  • Therapy
  • Bristol-Myers Squibb Company
  • Celgene Corporation

Global Bladder Cancer Therapeutics Market 2017-2021

  • $ 2500
  • May 2017
  • 70 pages

lymphoma, and acute lymphocytic leukemia.

  • Bladder Cancer
  • Lymphoma
  • Therapy
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
View report >

Lymphoma Statistics in the US

  • July 2017
  • 9 pages

These include studies in patients with relapsed or refractory Hodgkin lymphoma and CD##-expressing relapsed or refractory non-Hodgkin lymphomas, including T-cell lymphomas, diffuse large B-cell lymphoma (DLBCL), and other rare subtypes of Bcell malignancies, including mediastinal B-cell

  • Lymphoma
  • United States
  • Bristol-Myers Squibb Company
  • Immunomedics, Inc.
  • Seattle Genetics, Inc.

Therapy Market January 2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on